Background-Heart failure with preserved ejection fraction (HFpEF) represents a growing health burden associated with substantial mortality and morbidity. Consequently, risk prediction is of highest importance. Endothelial dysfunction has been recently shown to play an important role in the complex pathophysiology of HFpEF. We therefore aimed to assess von Willebrand factor (vWF), a marker of endothelial damage, as potential biomarker for risk assessment in patients with HFpEF. Methods and Results-Concentrations of vWF were assessed in 457 patients with HFpEF enrolled as part of the LUdwigshafen Risk and Cardiovascular Health (LURIC) study. All-cause mortality was observed in 40% of patients during a median follow-up time of 9.7 years. vWF significantly predicted mortality with a hazard ratio (HR) per increase of 1 SD of 1.45 (95% confidence interval, 1.26-1.68; P<0.001) and remained a significant predictor after adjustment for age, sex, body mass index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), renal function, and frequent HFpEFrelated comorbidities (adjusted HR per 1 SD, 1.22; 95% confidence interval, 1.05-1.42; P=0.001). Most notably, vWF showed additional prognostic value beyond that achievable with NT-proBNP indicated by improvements in C-Statistic (vWF×NT-proBNP: 0.65 versus NT-proBNP: 0.63; P for comparison, 0.004) and category-free net reclassification index (37.6%; P<0.001). Conclusions-vWF is an independent predictor of long-term outcome in patients with HFpEF, which is in line with endothelial dysfunction as potential mediator in the pathophysiology of HFpEF. In particular, combined assessment of vWF and NT-proBNP improved risk prediction in this vulnerable group of patients. (Circ Heart Fail. 2015;8:25-32.
H eart failure (HF) is traditionally defined as complex syndrome determined by a reduced left ventricular ejection fraction (HFrEF). However, more recent studies revealed, that approximately half of patients with HF present with a preserved ejection fraction (HFpEF). 1 HFpEF and HFrEF are thought to represent distinct entities of HF, both following different pathophysiologic mechanisms resulting in marked differences in myocardial structure and response to therapy. 2, 3 Consequently, individual strategies for tailored risk prediction in patients with HFpEF are inevitable. Natriuretic peptides have gained outstanding significance in diagnostic assessment and risk prediction of HF beyond conventional clinical risk predictors. 4 As patients with HFpEF typically present with lower concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), the prognostic validity might be limited in this group of patients. 5 Hence, assessment of additional markers reflecting different pathophysiologic pathways may improve risk prediction and facilitate the therapeutic management in patients with HFpEF. In this respect, Paulus et al 6 propose endothelial microvascular inflammation as potential mediator in the pathophysiology of HFpEF, which may induce myocardial stiffening and increased collagen deposition, both recognized as underlying mechanisms of cardiac fibrosis and diastolic dysfunction. In addition, peripheral endothelial function has been shown to be impaired in HFpEF and is further associated with an unfavorable prognosis. 7, 8 We therefore hypothesized that von Willebrand factor (vWF), a protein released in response to endothelial injury and involved in hemostasis and inflammatory activation, might be suitable for risk prediction in patients with HFpEF. 9, 10 To date, vWF has been shown to be associated with an enhanced number of cardiovascular events in high-risk populations such as patients with angina pectoris or HFrEF. 11, 12 However, to the best of our knowledge no data are available in patients with HFpEF. The aim of our study was to assess the prognostic value of plasma vWF concentrations in patients with HFpEF. In particular, we aimed to evaluate the predictive potential of combined assessment of vWF and NT-proBNP in relation to sole measurement of NT-proBNP in this group of patients.
Methods

Study Population
Study participants were enrolled as part of the LUdwigshafen Risk and Cardiovascular Health (LURIC) study. The detailed study protocol has been published previously. 13 In sum, 3316 patients referred for elective coronary angiography were enrolled between July 1997 and January 2000 in the Heart Center of Ludwigshafen. Inclusion criteria of the LURIC study were availability of a coronary angiogram and that patients were in a stable clinical condition. Patients with HFpEF were identified according to current guidelines of the Heart Failure and Echocardiography Associations of the European Society of Cardiology. The following criteria were used for the diagnosis of HFpEF: signs and symptoms of HF, a preserved left ventricular ejection fraction defined as EF ≥45% (echocardiographic or invasive), and evidence of diastolic dysfunction according to recommendations published by Paulus et al. In the majority of patients (73%), the diagnosis of diastolic HF was assessed based on invasive hemodynamic criteria (mean pulmonary capillary wedge pressure >12 mm Hg or a left ventricular end-diastolic pressure >16 mm Hg). After exclusion of acute or chronic infection, autoimmune diseases and cancer, 460 patients in stable condition remained in the final patient cohort. All study participants provided written informed consent. The LURIC study complies with the Declaration of Helsinki and was approved by the Ethics Committee of the Landesärztekammer Rheinland-Pfalz (Mainz, Germany).
Follow-Up and Study End Points
Primary study end points in this study were defined as death because of all causes as well as because of cardiovascular events. End points were assessed browsing local community registries. Death certificates were reviewed to categorize into cardiovascular and noncardiovascular causes of death. Cardiovascular mortality was defined as death because of fatal myocardial infarction, sudden cardiac death, death after cardiovascular intervention, stroke, and other causes of death because of cardiovascular diseases. A sample size of 460 patients with 40% of patients reaching the primary end point all-cause mortality allows to detect a risk ratio of 1.5 between first and third tertile (α=0.05, power=80%).
Blood Sampling and Laboratory Analyses
Blood sampling was done at the time of study enrollment. EDTA plasma samples were stored at −80° C after centrifugation (2800 rpm; 20 minutes) until analysis. vWF was measured by a turbidimetric immunoassay with polyclonal vWF antibodies (Stago Diagnostica/ Roche Mannheim, Germany). Measurement of NT-proBNP was assessed using the Elecsys 2010 NT-proBNP ELISA (Roche diagnostics, Mannheim, Germany). Routine laboratory parameters were analyzed according to the local laboratory standard procedures.
Statistical Analysis
Continuous data are expressed as median and Q1-Q3, discrete data as counts and percentages. Differences between groups were compared using Kruskal-Wallis test, Mann-Whitney U test and χ 2 test, where appropriate. Univariate and multivariable Cox proportional hazard regression models were used to calculate the predictive value of variables. Continuous variables including vWF were tested for normal distribution using Kolmogorov-Smirnov test and log transformed before analysis. In the multivariable models, vWF was adjusted for age, sex, body mass index, heart rate, New York Heart Association (NYHA) functional classification, NT-proBNP, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration), smoking, hypertension, coronary artery disease, diabetes mellitus, chronic obstructive pulmonary disease, and atrial fibrillation (model 1) and in addition for hemodynamics (left ventricular ejection fraction, left ventricular end-diastolic pressure, and pulmonary capillary wedge pressure) and physical activity (model 2), as well as for the inflammatory markers interleukin-6 (IL-6; model 3) and high-sensitivity C-reactive protein (hsCRP; model 4). Results were reported as the HR for a 1-SD increase of log-transformed continuous variables with the respective 95% confidence intervals. Interaction term analysis was used to assess a modification of the effect of variables used in the multivariable Cox-regression models on the predictive value of vWF. Kaplan-Meier curves of vWF were plotted and compared using the log-rank test. Harrell's C-statistic was used to assess the discriminatory power of biomarkers. An improvement in individual risk stratification of vWF in addition to NT-proBNP was examined using the category-free net reclassification improvement as described by Pencina et al. 14 A P value of <0.05 (2-tailed) was considered statistically significant. Statistical analyses were performed using SPSS 20.0 (IBM SPSS, USA) and STATA 13 (StataCorp, USA).
Results
Patient Characteristics
Of 460 patients in the final study cohort, plasma levels of vWF were available for 457 patients. Baseline characteristics according to vWF tertiles are provided in Table 1 . In addition, symptoms and measures of HFpEF are reported separately in Table 2 . In brief, patients had a median age of 67.9 years (Q1-Q3, 60.6-73.3 years) and a median NT-proBNP concentration of 533 pg/mL (Q1-Q3, 245-1305 pg/mL). A total of 63.5% of patients (n=292) were men, and 24.3% (n=112) were in New York Heart Association class III or IV. The median plasma concentration of vWF in the study cohort was 162 U/dL (Q1-Q3, 124-204 U/dL). Patients in higher tertiles of vWF were significantly older, had higher values of NTproBNP, had a worse physical exercise capacity, and presented with a worse renal function indicated by a positive correlation with creatinine and a negative correlation with estimated glomerular filtration rate. Moreover, they had lower erythrocyte concentrations and experienced more often AFib. Accordingly, patients in higher tertiles of vWF were more likely to be treated with vitamin K antagonists. The median plasma concentration of vWF in patients with sinus rhythm was 148 U/dL (Q1-Q3, 114-196) and 175 U/dL (Q1-Q3, 142-226) in patients with Afib (P<0.001). Finally, plasma levels of vWF were significantly associated with the inflammatory markers IL-6 (r=0.258, P<0.001) and hsCRP (r=0.298; P<0.001).
vWF and Risk Prediction
Patients were followed up for a median time of 9.7 years (Q1-Q3, 7.1-10.5 years). During this period, 184 (40%) patients experienced the primary end point all-cause mortality including 117 (25.6%) patients who died from cardiovascular causes. vWF demonstrated a strong predictive value in univariate Cox-regression analysis with a hours per 1 SD of 1.45 (95% confidence interval, 1.26-1.68; P<0.001) for allcause mortality (Table 3) . Five-year incidence rates according to tertiles of vWF were 11% in the first tertile, 15% in the second tertile, and 28% in the third tertile, respectively In addition, the Spearman ρ correlation coefficient was used to assess associations between plasma concentrations of von Willebrand factor and continuous variables (right column). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; bpm, beats per minutes; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HFpEF, heart failure with preserved ejection fraction; hsCRP, high-sensitivity C-reactive protein; MI, myocardial infarction; and vWF, von Willebrand factor.
( Figure 1 ; P for comparison <0.001; adjusted for model 1: P for comparison=0.026). After adjustment for demographics, NT-proBNP, renal function, and other established clinical predictive variables, vWF remained an independent predictor for all-cause mortality with a hours per 1 SD of 1.22 (95% confidence interval, 1.05-1.42; P=0.011; model 1). Additional adjustment for hemodynamics and physical activity (model 2) and for the inflammatory markers IL-6 (model 3) or hsCRP (model 4) did not affect the significant association of vWF with all-cause mortality (Table 3) . With regard to cardiovascular mortality, vWF was associated with this secondary end point with a hours per 1 SD of 1.37 (95% confidence interval, 1.14-1.64; P=0.001) in univariate analysis but lost significance after adjustment for clinical confounders (P=0.232) and after additional adjustment for IL-6 or hsCRP (Table 3) . Of note, apart from vWF only age, New York Heart Association class, NT-proBNP, and smoking were independent predictors of mortality in the multivariable model.
Although patients with concomitant AFib showed significantly higher concentrations of vWF compared with patients with sinus rhythm, interaction term analysis did not show a modification of the effect of vWF on survival by AFib (P=0.448). No other significant interaction between vWF and other variables of the multivariable models was found.
To analyze an additive prognostic value of vWF in relation to NT-proBNP, we stratified patients into 9 groups according to tertiles of vWF and NT-proBNP. We observed a gradually and mutual increase of risk for groups with higher tertiles of both biomarkers (Figure 2) . Compared with the reference group (patients in the lowest tertile of NT-proBNP and vWF), patients in the highest tertiles of NT-proBNP and vWF had a crude HR of 5.06 (P<0.001) and an adjusted HR of 2.94 (adjusted for model 1: P=0.002) for all-cause mortality as well as a crude HR of 5.07 (P<0.001) and an adjusted HR of 2.67 (adjusted for model 1: P=0.03) for cardiovascular mortality, respectively. Accordingly, combined assessment of both biomarkers showed a better discriminatory power (C-statistic: 0.65) than that of NT-proBNP alone (C-statistic: 0.63; P=0.004; Table 4 ). Finally, category-free net reclassification improvement analysis confirmed a significant Continuous data are given as median and Q1-Q3. Data were analyzed using Maentel-Haenszel χ 2 test for linear association or Kruskal-Wallis test for comparison of continuous data between tertiles of von Willebrand factor. HFpEF indicates heart failure with preserved ejection fraction; NYHA, New York Heart Association functional classification; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
improvement in individual risk prediction of vWF in addition to NT-proBNP with 37.6% (P<0.001; Table 4 ) for allcause mortality.
Discussion
In the present study, we evaluated the predictive value of vWF in 457 patients with HFpEF and a long-term followup time of ≈10 years. We could demonstrate that vWF is an independent predictor of mortality in patients with HFpEF, even after adjustment for established risk factors including age, sex, body mass index, NT-proBNP, renal function, and frequent HFpEF-related comorbidities. In particular, vWF revealed additive prognostic information beyond that achievable with NT-proBNP, which suggests vWF as complementary biomarker for refining risk prediction in this group of patients. vWF, a large multimeric glycoprotein predominantly produced in the Weibel-Palade bodies in endothelial cells plays a pivotal role in hemostasis by mediating platelet adhesion and aggregation under high shear conditions. 15 Raised levels of vWF are found in different states of endothelial damage and have therefore been considered as a marker of endothelial dysfunction. 16 Our findings of vWF as a marker of an adverse clinical course in HFpEF are consistent with recent publications. Borlaug et al 8 found an impaired endothelial function associated with reduced exercise capacity and a greater burden of symptoms in patients with HFpEF, which is in line with observations of elevated vWF levels in patients with decreased physical exercise capacity in the present analysis. Moreover, endothelial dysfunction assessed by peripheral arterial tonometry has been shown to be an independent predictor of cardiovascular events in patients with HFpEF. 7 As a further evidence of endothelial dysfunction involved in the pathophysiology of HFpEF, we found that the endothelial markers, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1, were also associated with an adverse prognosis in patients with HFpEF. However, plasma concentrations of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 were only available in a minor subgroup of the patient population (n=255; Table I in the Data Supplement).
In addition, Paulus et al recently published a novel pathophysiologic hypothesis for HFpEF proposing that a systemic inflammatory response driven by comorbidities may cause coronary microvascular endothelial inflammation and impairment of NO formation, which in further consequence contributes to myocardial stiffening and diastolic impairment over several downstream signaling pathways. 6 The link between inflammation and endothelial dysfunction is well established. Endothelial cells are activated under proinflammatory conditions and release enhanced amounts of vWF into the circulation. 9, 17 Conversely, vWF possesses intrinsic proinflammatory properties being capable to promote leukocyte recruitment, adhesion to endothelial layers, and extravasation toward the site of inflammation. [17] [18] [19] In our study, vWF was significantly associated with IL-6 and hsCRP. In addition, adjustment for IL-6 or hsCRP in multivariable Cox-regression leads to an attenuation of the predictive value of vWF, both supporting the preceding assumption of vWF being involved in inflammatory processes in patients with HFpEF. However, vWF turned out to be the more robust marker for risk prediction in our study cohort. To date, a variety of inflammatory mediators have been shown to be involved in the pathophysiology of HFpEF fostering the existence of an underlying systemic proinflammatory state with unfavorable impact on prognosis. [20] [21] [22] In conclusion, the independent association of vWF with mortality in patients with HFpEF may reflect its specific role at the interfaces between proinflammatory and prothrombotic activation as well as endothelial function, all mechanisms potentially involved in the pathopyhsiology of HFpEF. However, the study design used in the present analysis is not appropriate to prove causality or uncover potential mechanism of vWF in HFpEF.
To date, vWF has been shown to be a useful biomarker for prognosis in patients with HFrEF. 12, 23 Endothelial dysfunction driven by chronic immune activation is proposed to be closely linked with enhanced thrombogenesis in HFrEF and increased risk for cardiovascular events. 24, 25 In this respect, our findings that vWF is more closely associated with allcause mortality than with cardiovascular mortality including coronary events and stroke are rather conflicting. Certainly, this weaker association may be affected by a lower statistical power in consequence of a lower number of hard end points because of cardiovascular events. However, as HFpEF and HFrEF follow distinct pathophysiologic pathways, the role of vWF may be also different between both entities. Although the majority of deaths in patients with HFpEF are because of cardiovascular events with frequent sudden cardiac mortality, a higher proportion of patients die because of noncardiovascular causes compared with patients with HFrEF, which is mainly attributable to the advanced age and increased burden of comorbidities in HFpEF. 26 Consequently, the role of vWF in aging and common HF-related comorbidities has to be taken into account. First, we found a significant association of vWF with advanced age, which is in line with publications showing a continuous increase of plasma vWF concentrations with age. 11, 27 Second, vWF correlated with impaired renal function as indicated by a positive association with creatinine and a negative association with estimated glomerular filtration rate. Patel et al 28 found a trend toward a more pronounced renal impairment with increasing plasma levels of vWF in patients with nondialysis chronic kidney disease. The same study also showed an association with anemia in these patients, an observation which is consistent with results of our study showing a negative correlation between vWF and erythrocytes. Third, we found elevated concentrations of vWF in patients with concomitant AFib. In concordance, raised levels of vWF have been shown to be predictive of cardiovascular events and stroke in AFib, independent of treatment with vitamin K antagonists or aspirin. 29 Finally, there is also a sign for an association between vWF and fatal events related to infections in this HFpEF cohort suggesting that it may also be predictive for infections complicating the course of HFpEF. However, the number of fatal infections (n=17) is too low to make any final conclusions (data not shown). In summary, based on the aforementioned results one may speculate that vWF represents a biomarker of global risk in patients with HFpEF. However, future studies are necessary to confirm the predictive value of vWF in patients with HFpEF and clarify the exact pathophysiologic role. Further studies with sufficient thromboembolic and ischemic events, which may both occur with unknown frequency in HFpEF, may also clarify whether a specific association between vWF and mode of cardiovascular death exists in HFpEF.
Limitations
The majority of patients had been referred to coronary angiography because of evaluation of coronary artery disease and not in the course of a dedicated HF study. This may have biased the demographics of the study population and may limit the generalizability of data. However, sensitivity analysis for relevant baseline characteristics such as sex, age, New York Heart Association class, and HFpEF characterization by invasive measurements did not reveal any influence of these characteristics on the predictive value of vWF (Table II in the  Data Supplement) . As a further limitation, the retrospective diagnosis of HFpEF may have been less precise, in particular, for variables such as clinical symptoms. Finally, specific echocardiographic analyses for assessment of diastolic function were not routinely performed at the time of study enrollment. However, invasive hemodynamic measurements were available for the majority of patients, which is in accordance with current recommendations of Heart Failure and Echocardiography Associations of the European Society of Cardiology for the diagnosis of diastolic dysfunction.
Conclusions
In our study, vWF turned out as independent predictor of mortality in patients with HFpEF. To the best of our knowledge, this is the first work to demonstrate a prognostic value of a biomarker reflecting endothelial dysfunction/damage in patients with HFpEF and therefore may extend the current pathophysiologic knowledge of the disease. vWF was particularly suitable for risk prediction in addition to NT-proBNP, the current laboratory gold standard in HF, both representing different pathophysiologic pathways in HFpEF. Combined assessment of these biomarkers may improve individual risk prediction in this vulnerable and epidemiologically relevant group of patients.
